Document ID: chunk:federal_register_of_legislation:F2024L01524:schedule:1:p36
Version: federal_register_of_legislation:F2024L01524
Segment Type: schedule
Provision Reference: sch 1 (pt 36/38)
Character Range: 136207–140432

Chemotherapy or whole body radiotherapy,
                                                       b. High-dose corticosteroids (at least 20 mg of prednisone per day, or equivalent) for at least 14 days in a month, or pulse corticosteroid therapy,
                                                       c. Biological agents and other treatments that deplete or inhibit B cell or T cell function (abatacept, anti-CD20 antibodies, BTK inhibitors, JAK inhibitors, sphingosine 1-phosphate receptor modulators, anti-CD52 antibodies, anti-complement antibodies, anti-thymocyte globulin),
                                                       d. Selected conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) including mycophenolate, methotrexate, leflunomide, azathioprine, 6-mercaptopurine (at least 1.5mg/kg/day), alkylating agents (e.g. cyclophosphamide, chlorambucil), and systemic calcineurin inhibitors (e.g. cyclosporin, tacrolimus); OR
                                                       3. Any significantly immunocompromising condition(s) where, in the last 12 months the patient has received an anti-CD20 monoclonal antibody treatment, but criterion 2c above is not met; OR
                                                       4. Others with very high-risk conditions including Down Syndrome, cerebral palsy, congenital heart disease, thalassemia, sickle cell disease and other haemoglobinopathies; OR
                                                       5. People with disability with multiple comorbidities and/or frailty.
                                                       Details of the patient's medical condition necessitating use of this drug must be recorded in the patient's medical records
                                                       For the purpose of administering this restriction, signs or symptoms attributable to COVID-19 are: fever greater than 38 degrees Celsius, chills, cough, sore throat, shortness of breath or difficulty breathing with exertion, fatigue, nasal congestion, runny nose, headache, muscle or body aches, nausea, vomiting, diarrhea, loss of taste, loss of smell.
                                                       Access to this drug through this restriction is permitted irrespective of vaccination status.
                                                       Where nucleic acid testing is used to confirm diagnosis, the result, testing date, location and test provider must be recorded on the patient record.
                                                       Where a RAT is used to confirm diagnosis, available information about the test result, testing date, location and test provider (where relevant) must be recorded on the patient record.
                                                       This drug is not PBS-subsidised for pre-exposure or post-exposure prophylaxis for the prevention of SARS-CoV-2 infection.

[132] Schedule 4, Part 2, omit entry for Variation Code "V14812"
[133] Schedule 4, Part 2, omit entry for Variation Code "V14815"
[134] Schedule 4, Part 2, omit entry for Variation Code "V14819"
[135] Schedule 4, Part 2, omit entry for Variation Code "V14829"
[136] Schedule 5, after entry for Abacavir with lamivudine
insert:
Abiraterone  GRP-29273  Tablet containing abiraterone acetate 250 mg  Oral  Abiraterone-Teva
                                                                            Zytiga
Abiraterone  GRP-29283  Tablet containing abiraterone acetate 500 mg  Oral  Abiraterone-Teva
                                                                            Zytiga

[137] Schedule 5, after entry for Atorvastatin [GRP-20251]
insert:
Atovaquone  GRP-29277  Oral suspension 750 mg per 5 mL, 210 mL  Oral  ATOVACUE
                                                                      Wellvone

[138] Schedule 5, after entry for Buprenorphine [GRP-24293]
insert:
Cabergoline  GRP-19705  Tablet 500 micrograms  Oral  Dostamine
                                                     Dostinex

[139] Schedule 5, after entry for Clonazepam
insert:
Clonazepam  GRP-29271  Tablet 2 mg         Oral  Paxam 2
Clonazepam  GRP-29271  Tablet 2 mg (S19A)  Oral  Clonazepam USP (Advagen Pharma, USA)

[140] Schedule